Antiviral agent 35 

Antiviral agent 35 (compound 4d) is an orally active and potent influenza virus inhibitor, acting function in the early stage of virus replication. Antiviral agent 35 inhibits ROS accumulation, autophagy and apoptosis induced by influenza virus, and also inhibits inflammatory response mediated by RIG-1 pathway in mouse model with pulmonary infection. Antiviral agent 35 shows little cytotoxicity with CC₅₀ >800 μM in MDCK cells, and anti-H1N1 (A/Weiss/43) activity with EC₅₀ of 2.28 μM^[1].

EC50: 2.28 μM (HINI A/Weiss/43), 3.34 μM (A/Virginia/ATCC2/2009), 6.61 μM (A/Califomia/2014)^[1]

Antiviral agent 35 (compound 4d) (25 μM, 50 μM; 24-72 h) inhibits influenza virus replication in MDCK cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antiviral agent 35 (compound 4d) (25 mg/kg/d, 50 mg/kg/d, 100 mg/kg/d; by gavage; 2-6 d) attenuates pulmonary inflammation in mice on the 2nd, 4th and 6th day after H1N1 infection^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

418.47

C₂₃H₁₈N₂O₄S

2760972-52-7

O=[N+](C1=CC=C(C=C1)S(=O)(N(C2=CC=CC3=C2C=CC=C3)CC4=CC=CC=C4)=O)[O-]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ge Y, et al. Synthesis and pharmacodynamic evaluation of naphthalene derivatives against influenza A virus in vitro and in vivo. Eur J Med Chem. 2023 Nov 5;259:115660.  [Content Brief]